N-methyl-D-aspartate (NMDA) receptor blockers for the prevention of atherosclerosis
This invention relates to N-Methyl-D-Aspartate (NMDA) Receptor Blockers for the Prevention of Atherosclerosis. In addition, this invention relates to the unique homocysteine receptor and the blockage of this receptor in the prevention of atherosclerosis. This invention further relates to therapies u...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | Rosenquist, Thomas H Monaghan, Daniel T Gadson, Preston F Andaloro, Vincent J |
| description | This invention relates to N-Methyl-D-Aspartate (NMDA) Receptor Blockers for the Prevention of Atherosclerosis. In addition, this invention relates to the unique homocysteine receptor and the blockage of this receptor in the prevention of atherosclerosis. This invention further relates to therapies using NMDA Receptor Blockers, including blockers for a NMDA-like receptor.
The present invention relates to the novel finding that homocysteine affects the initiation and/or progress of atherosclerosis via a receptor-mediated growth factor effect on vascular smooth muscle cells. This growth factor effect can be inhibited by N-methyl-D-aspartate antagonists via a unique receptor that is in the NMDA receptor family. Through the use of cloning and other procedures, this homocysteine receptor can be characterized in order to develop novel pharmacologic strategies that the address the receptor for the prevention and treatment of atherosclerosis. |
| format | Patent |
| fullrecord | <record><control><sourceid>uspatents_EFH</sourceid><recordid>TN_cdi_uspatents_grants_06469027</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>06469027</sourcerecordid><originalsourceid>FETCH-uspatents_grants_064690273</originalsourceid><addsrcrecordid>eNrjZAj2081NLcmozNF10U0sLkgsKkksSVXQ8PN1cdRUKEpNTi0oyS9SSMrJT85OLSpWSANySjJSFQqKUstS80oy8_MU8tMUEoFCRfnFyTkgMrOYh4E1LTGnOJUXSnMzKLi5hjh76JYCLSgBaiuOTy9KBFEGZiZmlgZG5sZEKAEAnmg4yA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>N-methyl-D-aspartate (NMDA) receptor blockers for the prevention of atherosclerosis</title><source>USPTO Issued Patents</source><creator>Rosenquist, Thomas H ; Monaghan, Daniel T ; Gadson, Preston F ; Andaloro, Vincent J</creator><creatorcontrib>Rosenquist, Thomas H ; Monaghan, Daniel T ; Gadson, Preston F ; Andaloro, Vincent J ; The Board of Regents of the University of Nebraska</creatorcontrib><description>This invention relates to N-Methyl-D-Aspartate (NMDA) Receptor Blockers for the Prevention of Atherosclerosis. In addition, this invention relates to the unique homocysteine receptor and the blockage of this receptor in the prevention of atherosclerosis. This invention further relates to therapies using NMDA Receptor Blockers, including blockers for a NMDA-like receptor.
The present invention relates to the novel finding that homocysteine affects the initiation and/or progress of atherosclerosis via a receptor-mediated growth factor effect on vascular smooth muscle cells. This growth factor effect can be inhibited by N-methyl-D-aspartate antagonists via a unique receptor that is in the NMDA receptor family. Through the use of cloning and other procedures, this homocysteine receptor can be characterized in order to develop novel pharmacologic strategies that the address the receptor for the prevention and treatment of atherosclerosis.</description><language>eng</language><creationdate>2002</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6469027$$EPDF$$P50$$Guspatents$$Hfree_for_read</linktopdf><link.rule.ids>230,308,776,798,881,64012</link.rule.ids><linktorsrc>$$Uhttps://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6469027$$EView_record_in_USPTO$$FView_record_in_$$GUSPTO$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Rosenquist, Thomas H</creatorcontrib><creatorcontrib>Monaghan, Daniel T</creatorcontrib><creatorcontrib>Gadson, Preston F</creatorcontrib><creatorcontrib>Andaloro, Vincent J</creatorcontrib><creatorcontrib>The Board of Regents of the University of Nebraska</creatorcontrib><title>N-methyl-D-aspartate (NMDA) receptor blockers for the prevention of atherosclerosis</title><description>This invention relates to N-Methyl-D-Aspartate (NMDA) Receptor Blockers for the Prevention of Atherosclerosis. In addition, this invention relates to the unique homocysteine receptor and the blockage of this receptor in the prevention of atherosclerosis. This invention further relates to therapies using NMDA Receptor Blockers, including blockers for a NMDA-like receptor.
The present invention relates to the novel finding that homocysteine affects the initiation and/or progress of atherosclerosis via a receptor-mediated growth factor effect on vascular smooth muscle cells. This growth factor effect can be inhibited by N-methyl-D-aspartate antagonists via a unique receptor that is in the NMDA receptor family. Through the use of cloning and other procedures, this homocysteine receptor can be characterized in order to develop novel pharmacologic strategies that the address the receptor for the prevention and treatment of atherosclerosis.</description><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2002</creationdate><recordtype>patent</recordtype><sourceid>EFH</sourceid><recordid>eNrjZAj2081NLcmozNF10U0sLkgsKkksSVXQ8PN1cdRUKEpNTi0oyS9SSMrJT85OLSpWSANySjJSFQqKUstS80oy8_MU8tMUEoFCRfnFyTkgMrOYh4E1LTGnOJUXSnMzKLi5hjh76JYCLSgBaiuOTy9KBFEGZiZmlgZG5sZEKAEAnmg4yA</recordid><startdate>20021022</startdate><enddate>20021022</enddate><creator>Rosenquist, Thomas H</creator><creator>Monaghan, Daniel T</creator><creator>Gadson, Preston F</creator><creator>Andaloro, Vincent J</creator><scope>EFH</scope></search><sort><creationdate>20021022</creationdate><title>N-methyl-D-aspartate (NMDA) receptor blockers for the prevention of atherosclerosis</title><author>Rosenquist, Thomas H ; Monaghan, Daniel T ; Gadson, Preston F ; Andaloro, Vincent J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-uspatents_grants_064690273</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2002</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Rosenquist, Thomas H</creatorcontrib><creatorcontrib>Monaghan, Daniel T</creatorcontrib><creatorcontrib>Gadson, Preston F</creatorcontrib><creatorcontrib>Andaloro, Vincent J</creatorcontrib><creatorcontrib>The Board of Regents of the University of Nebraska</creatorcontrib><collection>USPTO Issued Patents</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Rosenquist, Thomas H</au><au>Monaghan, Daniel T</au><au>Gadson, Preston F</au><au>Andaloro, Vincent J</au><aucorp>The Board of Regents of the University of Nebraska</aucorp><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>N-methyl-D-aspartate (NMDA) receptor blockers for the prevention of atherosclerosis</title><date>2002-10-22</date><risdate>2002</risdate><abstract>This invention relates to N-Methyl-D-Aspartate (NMDA) Receptor Blockers for the Prevention of Atherosclerosis. In addition, this invention relates to the unique homocysteine receptor and the blockage of this receptor in the prevention of atherosclerosis. This invention further relates to therapies using NMDA Receptor Blockers, including blockers for a NMDA-like receptor.
The present invention relates to the novel finding that homocysteine affects the initiation and/or progress of atherosclerosis via a receptor-mediated growth factor effect on vascular smooth muscle cells. This growth factor effect can be inhibited by N-methyl-D-aspartate antagonists via a unique receptor that is in the NMDA receptor family. Through the use of cloning and other procedures, this homocysteine receptor can be characterized in order to develop novel pharmacologic strategies that the address the receptor for the prevention and treatment of atherosclerosis.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_uspatents_grants_06469027 |
| source | USPTO Issued Patents |
| title | N-methyl-D-aspartate (NMDA) receptor blockers for the prevention of atherosclerosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T18%3A35%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-uspatents_EFH&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Rosenquist,%20Thomas%20H&rft.aucorp=The%20Board%20of%20Regents%20of%20the%20University%20of%20Nebraska&rft.date=2002-10-22&rft_id=info:doi/&rft_dat=%3Cuspatents_EFH%3E06469027%3C/uspatents_EFH%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |